Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...
Dupilumab treatment in atopic dermatitis patients shows a 58% higher risk of developing psoriasis compared to other systemic treatments. The number needed to harm is 94, indicating a limited absolute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback